Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Forbion Capital Partners

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 111
Average round size
info
The average size of a deal this fund participated in
$35M
Portfolio companies 75
Rounds per year 6.94
Lead investments 26
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.32
Exits 38
Key employees 15
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Pharmaceutical
Summary

Forbion Capital Partners is the famous VC, which was founded in 2007. The company was established in Europe in The Netherlands. The leading representative office of defined VC is situated in the Naarden.

The fund has specific favorite in a number of founders of portfolio startups. If startup sums 3 or 4 of the founder, the chance for it to be financed is low. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline AM Pharma, Mitralign, BioVex Among the most popular fund investment industries, there are Clinical Trials, Health Diagnostics. For fund there is no match between the location of its establishment and the land of its numerous investments - United States.

The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Forbion Capital Partners, startups are often financed by Oxford Bioscience Partners, Giza Venture Capital, ABN AMRO Fund. The meaningful sponsors for the fund in investment in the same round are Oxford Bioscience Partners, New Science Ventures, Andera Partners. In the next rounds fund is usually obtained by Takeda Ventures, Oxford Bioscience Partners, NGN Capital.

The higher amount of exits for fund were in 2015. Speaking about the real fund results, this VC is 14 percentage points more often commits exit comparing to other organizations. The fund is constantly included in 2-6 investment rounds annually. Opposing the other organizations, this Forbion Capital Partners works on 10 percentage points more the average amount of lead investments. The average startup value when the investment from Forbion Capital Partners is 50-100 millions dollars. Deals in the range of 10 - 50 millions dollars are the general things for fund. The important activity for fund was in 2011. Despite it in 2019 the fund had an activity.

Besides them, we counted 10 critical employees of this fund in our database.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Forbion Capital Partners:
Typical Co-investors
Forbion Capital Partners is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Forbion Capital Partners:

Funds with similar focus

Funds from The Netherlands
Funds with similar focus located in The Netherlands:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

F2G

Biotechnology
Genetics
Health Care
Medical
Pharmaceutical
$70M04 Aug 2022 Manchester, England, United Kingdom

VectivBio

Biotechnology
Health Care
Medical
$54M29 Jun 2022 Basel, Basel-City, Switzerland

Precirix

Biotechnology
$94M16 Mar 2022 City of Brussels, Belgium

Complement Therapeutics

Biotechnology
Medical
$5M23 Feb 2022 London, England, United Kingdom

NorthSea Therapeutics

Biotechnology
Health Care
Therapeutics
$80M17 Dec 2021 The Netherlands, North Holland, Netherlands

Anaveon

Therapeutics
$119M16 Dec 2021 Basel-Country, Switzerland

Prilenia

Biotechnology
Pharmaceutical
$43M03 Nov 2021 Boston, Massachusetts, United States

Rectify Pharmaceuticals

Biotechnology
Life Science
Therapeutics
$100M14 Oct 2021 Cambridge, Massachusetts, United States

NeRRe Therapeutics

Biotechnology
Health Care
Medical
$27M07 Jul 2021 United Kingdom, England, United Kingdom
News
VectorY Raises €31 Million in Seed Financing to Develop Next-Generation Gene Therapies Aimed at Muscular and CNS Disorders

– VectorY Therapeutics announced the completion of a €31m seed financing round.
– The oversubscribed round was co-led by founding investor Forbion and a leading global investment firm. BGV and Eli Lilly and Company also joined the syndicate.
– The proceeds from this seed financing will be used by the Company to establish pre-clinical proof of concept for vectorized antibodies in target indications of ALS and Alzheimer’s.
– The Company will also use the funds to establish proprietary manufacturing capabilities, including a state-of-the-art GMP facility in the Netherlands.
– The Company also announced the appointment of a new Chief Executive Officer, Alexander Vos, and Chief Technology Officer Dr. Sander van Deventer, both highly experienced pioneers in the cell and gene therapy field.

Numab Therapeutics Completes Oversubscribed CHF 100 Million Series C Financing

– Numab Therapeutics AG, a clinical stage biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer and inflammation, announced the closing of a CHF 100 million (approximately USD 110 million) Series C financing.
– The financing was co-led by new investors Novo Holdings and HBM Partners, with participation from additional new investors Forbion via its Forbion Growth Opportunities Fund, Cormorant Asset Management, BVF Partners L.P., RTW Investments L.P., funds and accounts under the management of BlackRock, Octagon Capital Advisors, and existing investors.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Forbion Capital Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: